The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.
October 21st 2024
Novo Nordisk will present more detailed data in 2025 and plans to file for an expanded label for Rybelsus for this population.
HCPLive Endocrinology's flagship diabetes podcast, hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP
Canagliflozin Does Not Increase Risk of Amputation, Despite Boxed Warning
June 29th 2018In a comparison of canagliflozin to other SGLT-2 inhibitors and anti-hyperglycemic therapies, the drug was found to decrease hospitalization from heart failure risk, and carry no extra risk for leg or foot amputation.